nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CA14—Furosemide—dilated cardiomyopathy	0.119	0.169	CbGbCtD
Imatinib—CA6—Furosemide—dilated cardiomyopathy	0.113	0.16	CbGbCtD
Imatinib—CA7—Furosemide—dilated cardiomyopathy	0.0984	0.139	CbGbCtD
Imatinib—CA9—Furosemide—dilated cardiomyopathy	0.0845	0.12	CbGbCtD
Imatinib—CA12—Furosemide—dilated cardiomyopathy	0.0845	0.12	CbGbCtD
Imatinib—CA1—Furosemide—dilated cardiomyopathy	0.079	0.112	CbGbCtD
Imatinib—CA2—Furosemide—dilated cardiomyopathy	0.0683	0.0968	CbGbCtD
Imatinib—ALB—Furosemide—dilated cardiomyopathy	0.0224	0.0317	CbGbCtD
Imatinib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0195	0.0276	CbGbCtD
Imatinib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0171	0.0243	CbGbCtD
Imatinib—CA3—pericardium—dilated cardiomyopathy	0.00816	0.122	CbGeAlD
Imatinib—CYP2C9—cardial valve—dilated cardiomyopathy	0.00702	0.105	CbGeAlD
Imatinib—DDR1—cardiac ventricle—dilated cardiomyopathy	0.00326	0.0486	CbGeAlD
Imatinib—DDR1—myocardium—dilated cardiomyopathy	0.00307	0.0457	CbGeAlD
Imatinib—ABCA3—heart—dilated cardiomyopathy	0.00232	0.0345	CbGeAlD
Imatinib—DDR1—heart—dilated cardiomyopathy	0.00214	0.0319	CbGeAlD
Imatinib—CA3—cardiac ventricle—dilated cardiomyopathy	0.00192	0.0286	CbGeAlD
Imatinib—PIP4K2C—myocardium—dilated cardiomyopathy	0.00189	0.0282	CbGeAlD
Imatinib—DDR1—cardiac atrium—dilated cardiomyopathy	0.00183	0.0273	CbGeAlD
Imatinib—CA3—myocardium—dilated cardiomyopathy	0.00181	0.0269	CbGeAlD
Imatinib—CA14—cardiac ventricle—dilated cardiomyopathy	0.00174	0.026	CbGeAlD
Imatinib—NQO2—cardiac ventricle—dilated cardiomyopathy	0.00148	0.022	CbGeAlD
Imatinib—ABL2—heart—dilated cardiomyopathy	0.0014	0.0208	CbGeAlD
Imatinib—NQO2—myocardium—dilated cardiomyopathy	0.00139	0.0207	CbGeAlD
Imatinib—PIP4K2C—heart—dilated cardiomyopathy	0.00132	0.0197	CbGeAlD
Imatinib—CA3—heart—dilated cardiomyopathy	0.00126	0.0188	CbGeAlD
Imatinib—LCK—heart—dilated cardiomyopathy	0.00117	0.0175	CbGeAlD
Imatinib—PDGFRB—cardiac ventricle—dilated cardiomyopathy	0.00115	0.0171	CbGeAlD
Imatinib—CA14—heart—dilated cardiomyopathy	0.00114	0.0171	CbGeAlD
Imatinib—PIP4K2C—cardiac atrium—dilated cardiomyopathy	0.00113	0.0168	CbGeAlD
Imatinib—KIT—myocardium—dilated cardiomyopathy	0.00111	0.0165	CbGeAlD
Imatinib—PDGFRB—myocardium—dilated cardiomyopathy	0.00108	0.0161	CbGeAlD
Imatinib—CA3—cardiac atrium—dilated cardiomyopathy	0.00108	0.0161	CbGeAlD
Imatinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.00103	0.0153	CbGeAlD
Imatinib—CA14—cardiac atrium—dilated cardiomyopathy	0.000979	0.0146	CbGeAlD
Imatinib—NQO2—heart—dilated cardiomyopathy	0.00097	0.0145	CbGeAlD
Imatinib—PDGFRA—heart—dilated cardiomyopathy	0.000967	0.0144	CbGeAlD
Imatinib—ABL1—myocardium—dilated cardiomyopathy	0.000965	0.0144	CbGeAlD
Imatinib—CSF1R—heart—dilated cardiomyopathy	0.000852	0.0127	CbGeAlD
Imatinib—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.000837	0.00639	CcSEcCtD
Imatinib—NQO2—cardiac atrium—dilated cardiomyopathy	0.000829	0.0124	CbGeAlD
Imatinib—Hearing impaired—Furosemide—dilated cardiomyopathy	0.000828	0.00632	CcSEcCtD
Imatinib—Throat sore—Lisinopril—dilated cardiomyopathy	0.00082	0.00627	CcSEcCtD
Imatinib—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.000813	0.00621	CcSEcCtD
Imatinib—Vasculitis—Furosemide—dilated cardiomyopathy	0.000807	0.00617	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.000803	0.00614	CcSEcCtD
Imatinib—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.000802	0.00613	CcSEcCtD
Imatinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.000796	0.00608	CcSEcCtD
Imatinib—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.000785	0.006	CcSEcCtD
Imatinib—SLC47A1—heart—dilated cardiomyopathy	0.000778	0.0116	CbGeAlD
Imatinib—KIT—heart—dilated cardiomyopathy	0.000773	0.0115	CbGeAlD
Imatinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.000772	0.0059	CcSEcCtD
Imatinib—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000756	0.00578	CcSEcCtD
Imatinib—PDGFRB—heart—dilated cardiomyopathy	0.000755	0.0113	CbGeAlD
Imatinib—Memory impairment—Lisinopril—dilated cardiomyopathy	0.000753	0.00575	CcSEcCtD
Imatinib—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00074	0.00565	CcSEcCtD
Imatinib—CSF1R—cardiac atrium—dilated cardiomyopathy	0.000728	0.0109	CbGeAlD
Imatinib—CA1—heart—dilated cardiomyopathy	0.000707	0.0105	CbGeAlD
Imatinib—Lightheadedness—Furosemide—dilated cardiomyopathy	0.000705	0.00539	CcSEcCtD
Imatinib—CA2—cardiac ventricle—dilated cardiomyopathy	0.000698	0.0104	CbGeAlD
Imatinib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000688	0.00525	CcSEcCtD
Imatinib—ABL1—heart—dilated cardiomyopathy	0.000673	0.01	CbGeAlD
Imatinib—CA2—myocardium—dilated cardiomyopathy	0.000657	0.00979	CbGeAlD
Imatinib—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00065	0.00497	CcSEcCtD
Imatinib—PDGFRB—cardiac atrium—dilated cardiomyopathy	0.000646	0.00963	CbGeAlD
Imatinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.000643	0.00491	CcSEcCtD
Imatinib—Deafness—Furosemide—dilated cardiomyopathy	0.000639	0.00488	CcSEcCtD
Imatinib—Vascular purpura—Furosemide—dilated cardiomyopathy	0.000639	0.00488	CcSEcCtD
Imatinib—Drug interaction—Lisinopril—dilated cardiomyopathy	0.000637	0.00487	CcSEcCtD
Imatinib—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.000633	0.00484	CcSEcCtD
Imatinib—Gout—Lisinopril—dilated cardiomyopathy	0.000633	0.00484	CcSEcCtD
Imatinib—ALB—heart—dilated cardiomyopathy	0.000621	0.00926	CbGeAlD
Imatinib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000621	0.00474	CcSEcCtD
Imatinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000609	0.00465	CcSEcCtD
Imatinib—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000606	0.00463	CcSEcCtD
Imatinib—Vasculitis—Lisinopril—dilated cardiomyopathy	0.000606	0.00463	CcSEcCtD
Imatinib—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000598	0.00457	CcSEcCtD
Imatinib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000598	0.00457	CcSEcCtD
Imatinib—Purpura—Furosemide—dilated cardiomyopathy	0.000593	0.00453	CcSEcCtD
Imatinib—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000587	0.00449	CcSEcCtD
Imatinib—Lethargy—Furosemide—dilated cardiomyopathy	0.000584	0.00446	CcSEcCtD
Imatinib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000581	0.00444	CcSEcCtD
Imatinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000576	0.00858	CbGeAlD
Imatinib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000574	0.00439	CcSEcCtD
Imatinib—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000574	0.00439	CcSEcCtD
Imatinib—Malaise—Spironolactone—dilated cardiomyopathy	0.000571	0.00436	CcSEcCtD
Imatinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000567	0.00433	CcSEcCtD
Imatinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000561	0.00429	CcSEcCtD
Imatinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000536	0.00409	CcSEcCtD
Imatinib—Discomfort—Spironolactone—dilated cardiomyopathy	0.000532	0.00407	CcSEcCtD
Imatinib—Dehydration—Furosemide—dilated cardiomyopathy	0.000532	0.00406	CcSEcCtD
Imatinib—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000529	0.00404	CcSEcCtD
Imatinib—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000526	0.00402	CcSEcCtD
Imatinib—Confusional state—Spironolactone—dilated cardiomyopathy	0.000521	0.00398	CcSEcCtD
Imatinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00052	0.00398	CcSEcCtD
Imatinib—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000517	0.00395	CcSEcCtD
Imatinib—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000515	0.00393	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000515	0.00393	CcSEcCtD
Imatinib—PTGS1—myocardium—dilated cardiomyopathy	0.000507	0.00756	CbGeAlD
Imatinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000506	0.00387	CcSEcCtD
Imatinib—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000504	0.00385	CcSEcCtD
Imatinib—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000498	0.0038	CcSEcCtD
Imatinib—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000489	0.00374	CcSEcCtD
Imatinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000485	0.0037	CcSEcCtD
Imatinib—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000484	0.0037	CcSEcCtD
Imatinib—Eczema—Lisinopril—dilated cardiomyopathy	0.000477	0.00365	CcSEcCtD
Imatinib—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.000477	0.00365	CcSEcCtD
Imatinib—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.000475	0.00363	CcSEcCtD
Imatinib—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000465	0.00355	CcSEcCtD
Imatinib—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000463	0.00354	CcSEcCtD
Imatinib—Somnolence—Spironolactone—dilated cardiomyopathy	0.000459	0.00351	CcSEcCtD
Imatinib—CA2—heart—dilated cardiomyopathy	0.000458	0.00683	CbGeAlD
Imatinib—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000457	0.00349	CcSEcCtD
Imatinib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000453	0.00346	CcSEcCtD
Imatinib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000451	0.00345	CcSEcCtD
Imatinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000446	0.00341	CcSEcCtD
Imatinib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000446	0.00341	CcSEcCtD
Imatinib—Arthritis—Lisinopril—dilated cardiomyopathy	0.000441	0.00337	CcSEcCtD
Imatinib—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00044	0.00336	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000437	0.00334	CcSEcCtD
Imatinib—Renal failure—Furosemide—dilated cardiomyopathy	0.000433	0.00331	CcSEcCtD
Imatinib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000431	0.00329	CcSEcCtD
Imatinib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000429	0.00328	CcSEcCtD
Imatinib—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000426	0.00325	CcSEcCtD
Imatinib—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000426	0.00325	CcSEcCtD
Imatinib—ABCG2—heart—dilated cardiomyopathy	0.000425	0.00633	CbGeAlD
Imatinib—Sweating—Furosemide—dilated cardiomyopathy	0.000422	0.00323	CcSEcCtD
Imatinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000417	0.00318	CcSEcCtD
Imatinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.000414	0.00317	CcSEcCtD
Imatinib—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000411	0.00314	CcSEcCtD
Imatinib—Urticaria—Spironolactone—dilated cardiomyopathy	0.00041	0.00314	CcSEcCtD
Imatinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000408	0.00312	CcSEcCtD
Imatinib—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000408	0.00312	CcSEcCtD
Imatinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000402	0.00307	CcSEcCtD
Imatinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000399	0.00305	CcSEcCtD
Imatinib—CA2—cardiac atrium—dilated cardiomyopathy	0.000392	0.00584	CbGeAlD
Imatinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000391	0.00299	CcSEcCtD
Imatinib—CYP2C9—heart—dilated cardiomyopathy	0.000388	0.00578	CbGeAlD
Imatinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000388	0.00296	CcSEcCtD
Imatinib—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000388	0.00296	CcSEcCtD
Imatinib—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000386	0.00295	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000386	0.00295	CcSEcCtD
Imatinib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000384	0.00293	CcSEcCtD
Imatinib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000381	0.00291	CcSEcCtD
Imatinib—Gastritis—Lisinopril—dilated cardiomyopathy	0.00038	0.0029	CcSEcCtD
Imatinib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000374	0.00286	CcSEcCtD
Imatinib—Influenza—Lisinopril—dilated cardiomyopathy	0.000371	0.00283	CcSEcCtD
Imatinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.00037	0.00283	CcSEcCtD
Imatinib—Tinnitus—Furosemide—dilated cardiomyopathy	0.000369	0.00282	CcSEcCtD
Imatinib—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000367	0.00281	CcSEcCtD
Imatinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000366	0.00279	CcSEcCtD
Imatinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000364	0.00278	CcSEcCtD
Imatinib—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000361	0.00276	CcSEcCtD
Imatinib—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000361	0.00276	CcSEcCtD
Imatinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000359	0.00274	CcSEcCtD
Imatinib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000357	0.00273	CcSEcCtD
Imatinib—PTGS1—heart—dilated cardiomyopathy	0.000354	0.00528	CbGeAlD
Imatinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000353	0.0027	CcSEcCtD
Imatinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000353	0.0027	CcSEcCtD
Imatinib—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000352	0.00269	CcSEcCtD
Imatinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000347	0.00265	CcSEcCtD
Imatinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000345	0.00263	CcSEcCtD
Imatinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000344	0.00263	CcSEcCtD
Imatinib—Erythema—Furosemide—dilated cardiomyopathy	0.000344	0.00263	CcSEcCtD
Imatinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000342	0.00261	CcSEcCtD
Imatinib—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000342	0.00261	CcSEcCtD
Imatinib—Flatulence—Furosemide—dilated cardiomyopathy	0.000339	0.00259	CcSEcCtD
Imatinib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000338	0.00259	CcSEcCtD
Imatinib—Weight increased—Lisinopril—dilated cardiomyopathy	0.000337	0.00258	CcSEcCtD
Imatinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000337	0.00258	CcSEcCtD
Imatinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000336	0.00256	CcSEcCtD
Imatinib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000335	0.00256	CcSEcCtD
Imatinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000333	0.00254	CcSEcCtD
Imatinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000331	0.00253	CcSEcCtD
Imatinib—Depression—Lisinopril—dilated cardiomyopathy	0.00033	0.00252	CcSEcCtD
Imatinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000328	0.00251	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000328	0.0025	CcSEcCtD
Imatinib—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000326	0.00249	CcSEcCtD
Imatinib—Rash—Spironolactone—dilated cardiomyopathy	0.000326	0.00249	CcSEcCtD
Imatinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000325	0.00249	CcSEcCtD
Imatinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000325	0.00248	CcSEcCtD
Imatinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000325	0.00248	CcSEcCtD
Imatinib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000324	0.00248	CcSEcCtD
Imatinib—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000324	0.00248	CcSEcCtD
Imatinib—Headache—Spironolactone—dilated cardiomyopathy	0.000324	0.00247	CcSEcCtD
Imatinib—Jaundice—Lisinopril—dilated cardiomyopathy	0.000322	0.00246	CcSEcCtD
Imatinib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000321	0.00246	CcSEcCtD
Imatinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000318	0.00243	CcSEcCtD
Imatinib—Sweating—Lisinopril—dilated cardiomyopathy	0.000317	0.00242	CcSEcCtD
Imatinib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000315	0.00241	CcSEcCtD
Imatinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000313	0.00239	CcSEcCtD
Imatinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000312	0.00238	CcSEcCtD
Imatinib—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00031	0.00237	CcSEcCtD
Imatinib—Vertigo—Furosemide—dilated cardiomyopathy	0.000309	0.00236	CcSEcCtD
Imatinib—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000309	0.00236	CcSEcCtD
Imatinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.000308	0.00236	CcSEcCtD
Imatinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000307	0.00234	CcSEcCtD
Imatinib—PTGS1—cardiac atrium—dilated cardiomyopathy	0.000303	0.00451	CbGeAlD
Imatinib—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000298	0.00227	CcSEcCtD
Imatinib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000297	0.00227	CcSEcCtD
Imatinib—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000295	0.00225	CcSEcCtD
Imatinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000293	0.00224	CcSEcCtD
Imatinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000292	0.00223	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000291	0.00222	CcSEcCtD
Imatinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000291	0.00222	CcSEcCtD
Imatinib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000287	0.00219	CcSEcCtD
Imatinib—Confusional state—Furosemide—dilated cardiomyopathy	0.000283	0.00217	CcSEcCtD
Imatinib—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000281	0.00215	CcSEcCtD
Imatinib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000281	0.00214	CcSEcCtD
Imatinib—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000277	0.00211	CcSEcCtD
Imatinib—Shock—Furosemide—dilated cardiomyopathy	0.000277	0.00211	CcSEcCtD
Imatinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000276	0.00211	CcSEcCtD
Imatinib—Flushing—Lisinopril—dilated cardiomyopathy	0.000275	0.00211	CcSEcCtD
Imatinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000275	0.0021	CcSEcCtD
Imatinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000273	0.00209	CcSEcCtD
Imatinib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000272	0.00208	CcSEcCtD
Imatinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000269	0.00206	CcSEcCtD
Imatinib—Anorexia—Furosemide—dilated cardiomyopathy	0.000268	0.00205	CcSEcCtD
Imatinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000268	0.00204	CcSEcCtD
Imatinib—Chills—Lisinopril—dilated cardiomyopathy	0.000266	0.00204	CcSEcCtD
Imatinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000265	0.00203	CcSEcCtD
Imatinib—Hypotension—Furosemide—dilated cardiomyopathy	0.000263	0.00201	CcSEcCtD
Imatinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000262	0.002	CcSEcCtD
Imatinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00026	0.00199	CcSEcCtD
Imatinib—Erythema—Lisinopril—dilated cardiomyopathy	0.000258	0.00197	CcSEcCtD
Imatinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000258	0.00197	CcSEcCtD
Imatinib—Flatulence—Lisinopril—dilated cardiomyopathy	0.000255	0.00195	CcSEcCtD
Imatinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000253	0.00193	CcSEcCtD
Imatinib—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000252	0.00193	CcSEcCtD
Imatinib—Back pain—Lisinopril—dilated cardiomyopathy	0.00025	0.00191	CcSEcCtD
Imatinib—Somnolence—Furosemide—dilated cardiomyopathy	0.00025	0.00191	CcSEcCtD
Imatinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000248	0.0019	CcSEcCtD
Imatinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000244	0.00187	CcSEcCtD
Imatinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000244	0.00186	CcSEcCtD
Imatinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000243	0.00185	CcSEcCtD
Imatinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000242	0.00185	CcSEcCtD
Imatinib—Tremor—Lisinopril—dilated cardiomyopathy	0.000242	0.00185	CcSEcCtD
Imatinib—Pain—Furosemide—dilated cardiomyopathy	0.00024	0.00184	CcSEcCtD
Imatinib—Constipation—Furosemide—dilated cardiomyopathy	0.00024	0.00184	CcSEcCtD
Imatinib—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00024	0.00183	CcSEcCtD
Imatinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000239	0.00182	CcSEcCtD
Imatinib—Angioedema—Lisinopril—dilated cardiomyopathy	0.000236	0.0018	CcSEcCtD
Imatinib—Malaise—Lisinopril—dilated cardiomyopathy	0.000233	0.00178	CcSEcCtD
Imatinib—Vertigo—Lisinopril—dilated cardiomyopathy	0.000232	0.00177	CcSEcCtD
Imatinib—Syncope—Lisinopril—dilated cardiomyopathy	0.000232	0.00177	CcSEcCtD
Imatinib—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000232	0.00177	CcSEcCtD
Imatinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000231	0.00177	CcSEcCtD
Imatinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00023	0.00176	CcSEcCtD
Imatinib—Palpitations—Lisinopril—dilated cardiomyopathy	0.000228	0.00174	CcSEcCtD
Imatinib—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000227	0.00174	CcSEcCtD
Imatinib—Cough—Lisinopril—dilated cardiomyopathy	0.000225	0.00172	CcSEcCtD
Imatinib—Urticaria—Furosemide—dilated cardiomyopathy	0.000223	0.00171	CcSEcCtD
Imatinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000222	0.0017	CcSEcCtD
Imatinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000222	0.0017	CcSEcCtD
Imatinib—Chest pain—Lisinopril—dilated cardiomyopathy	0.00022	0.00168	CcSEcCtD
Imatinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.00022	0.00168	CcSEcCtD
Imatinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00022	0.00168	CcSEcCtD
Imatinib—Anxiety—Lisinopril—dilated cardiomyopathy	0.000219	0.00168	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000218	0.00167	CcSEcCtD
Imatinib—Discomfort—Lisinopril—dilated cardiomyopathy	0.000217	0.00166	CcSEcCtD
Imatinib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000215	0.00164	CcSEcCtD
Imatinib—Confusional state—Lisinopril—dilated cardiomyopathy	0.000213	0.00162	CcSEcCtD
Imatinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000211	0.00161	CcSEcCtD
Imatinib—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000211	0.00161	CcSEcCtD
Imatinib—Infection—Lisinopril—dilated cardiomyopathy	0.00021	0.0016	CcSEcCtD
Imatinib—ABCB1—heart—dilated cardiomyopathy	0.000209	0.00312	CbGeAlD
Imatinib—Shock—Lisinopril—dilated cardiomyopathy	0.000207	0.00159	CcSEcCtD
Imatinib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000207	0.00158	CcSEcCtD
Imatinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000206	0.00158	CcSEcCtD
Imatinib—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000206	0.00157	CcSEcCtD
Imatinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000205	0.00157	CcSEcCtD
Imatinib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000204	0.00156	CcSEcCtD
Imatinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000202	0.00154	CcSEcCtD
Imatinib—Anorexia—Lisinopril—dilated cardiomyopathy	0.000201	0.00154	CcSEcCtD
Imatinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000199	0.00152	CcSEcCtD
Imatinib—Hypotension—Lisinopril—dilated cardiomyopathy	0.000197	0.00151	CcSEcCtD
Imatinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000192	0.00147	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000192	0.00147	CcSEcCtD
Imatinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000191	0.00146	CcSEcCtD
Imatinib—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000189	0.00145	CcSEcCtD
Imatinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000188	0.00144	CcSEcCtD
Imatinib—Somnolence—Lisinopril—dilated cardiomyopathy	0.000187	0.00143	CcSEcCtD
Imatinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000186	0.00142	CcSEcCtD
Imatinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000186	0.00142	CcSEcCtD
Imatinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000183	0.0014	CcSEcCtD
Imatinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000182	0.00139	CcSEcCtD
Imatinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000182	0.00139	CcSEcCtD
Imatinib—Pain—Lisinopril—dilated cardiomyopathy	0.00018	0.00138	CcSEcCtD
Imatinib—Constipation—Lisinopril—dilated cardiomyopathy	0.00018	0.00138	CcSEcCtD
Imatinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000179	0.00137	CcSEcCtD
Imatinib—Rash—Furosemide—dilated cardiomyopathy	0.000177	0.00135	CcSEcCtD
Imatinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000177	0.00135	CcSEcCtD
Imatinib—Headache—Furosemide—dilated cardiomyopathy	0.000176	0.00135	CcSEcCtD
Imatinib—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000174	0.00133	CcSEcCtD
Imatinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000172	0.00132	CcSEcCtD
Imatinib—Urticaria—Lisinopril—dilated cardiomyopathy	0.000168	0.00128	CcSEcCtD
Imatinib—Nausea—Furosemide—dilated cardiomyopathy	0.000167	0.00128	CcSEcCtD
Imatinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000167	0.00127	CcSEcCtD
Imatinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000167	0.00127	CcSEcCtD
Imatinib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000155	0.00119	CcSEcCtD
Imatinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000151	0.00116	CcSEcCtD
Imatinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000149	0.00114	CcSEcCtD
Imatinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000144	0.0011	CcSEcCtD
Imatinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000139	0.00107	CcSEcCtD
Imatinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000134	0.00102	CcSEcCtD
Imatinib—Rash—Lisinopril—dilated cardiomyopathy	0.000133	0.00102	CcSEcCtD
Imatinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000133	0.00102	CcSEcCtD
Imatinib—Headache—Lisinopril—dilated cardiomyopathy	0.000132	0.00101	CcSEcCtD
Imatinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000125	0.000957	CcSEcCtD
Imatinib—LCK—Downstream signal transduction—EGFR—dilated cardiomyopathy	2.48e-05	0.000257	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—EGFR—dilated cardiomyopathy	2.47e-05	0.000256	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	2.46e-05	0.000255	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—EGFR—dilated cardiomyopathy	2.46e-05	0.000255	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—RAC1—dilated cardiomyopathy	2.45e-05	0.000254	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—EGFR—dilated cardiomyopathy	2.44e-05	0.000253	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.42e-05	0.000251	CbGpPWpGaD
Imatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	2.41e-05	0.00025	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—RAC1—dilated cardiomyopathy	2.39e-05	0.000247	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—RAC1—dilated cardiomyopathy	2.35e-05	0.000244	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ITGB1—dilated cardiomyopathy	2.35e-05	0.000243	CbGpPWpGaD
Imatinib—ALB—Metabolism—TAZ—dilated cardiomyopathy	2.35e-05	0.000243	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.35e-05	0.000243	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	2.32e-05	0.000241	CbGpPWpGaD
Imatinib—LCK—Hemostasis—CD36—dilated cardiomyopathy	2.32e-05	0.00024	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	2.3e-05	0.000238	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—EGFR—dilated cardiomyopathy	2.3e-05	0.000238	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	2.3e-05	0.000238	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	2.29e-05	0.000237	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—EGFR—dilated cardiomyopathy	2.29e-05	0.000237	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—RAF1—dilated cardiomyopathy	2.28e-05	0.000237	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—EGFR—dilated cardiomyopathy	2.28e-05	0.000236	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	2.26e-05	0.000234	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—EGFR—dilated cardiomyopathy	2.25e-05	0.000233	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	2.24e-05	0.000232	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—RAF1—dilated cardiomyopathy	2.23e-05	0.000232	CbGpPWpGaD
Imatinib—CA2—Metabolism—GPX1—dilated cardiomyopathy	2.19e-05	0.000227	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	2.19e-05	0.000227	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	2.19e-05	0.000227	CbGpPWpGaD
Imatinib—LCK—Hemostasis—RAC1—dilated cardiomyopathy	2.18e-05	0.000226	CbGpPWpGaD
Imatinib—LCK—Disease—NPPA—dilated cardiomyopathy	2.17e-05	0.000225	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—EGFR—dilated cardiomyopathy	2.17e-05	0.000225	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.15e-05	0.000223	CbGpPWpGaD
Imatinib—CA2—Metabolism—CD36—dilated cardiomyopathy	2.14e-05	0.000221	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—EGFR—dilated cardiomyopathy	2.13e-05	0.000221	CbGpPWpGaD
Imatinib—ALB—Metabolism—SDHA—dilated cardiomyopathy	2.12e-05	0.00022	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	2.11e-05	0.000218	CbGpPWpGaD
Imatinib—CA1—Metabolism—GPX1—dilated cardiomyopathy	2.1e-05	0.000218	CbGpPWpGaD
Imatinib—LCK—Disease—PSEN2—dilated cardiomyopathy	2.1e-05	0.000218	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD36—dilated cardiomyopathy	2.09e-05	0.000216	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—RAF1—dilated cardiomyopathy	2.08e-05	0.000216	CbGpPWpGaD
Imatinib—KIT—Immune System—ITGB1—dilated cardiomyopathy	2.08e-05	0.000216	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	2.06e-05	0.000214	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	2.06e-05	0.000213	CbGpPWpGaD
Imatinib—CA1—Metabolism—CD36—dilated cardiomyopathy	2.05e-05	0.000212	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	2.04e-05	0.000212	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	2.04e-05	0.000211	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.04e-05	0.000211	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.02e-05	0.000209	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2e-05	0.000208	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD36—dilated cardiomyopathy	2e-05	0.000208	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ITGB1—dilated cardiomyopathy	1.97e-05	0.000204	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—RAC1—dilated cardiomyopathy	1.97e-05	0.000204	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.96e-05	0.000203	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—EGFR—dilated cardiomyopathy	1.95e-05	0.000202	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	1.94e-05	0.000201	CbGpPWpGaD
Imatinib—CA2—Metabolism—AGT—dilated cardiomyopathy	1.92e-05	0.000199	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	1.92e-05	0.000199	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.91e-05	0.000198	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.91e-05	0.000198	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	1.91e-05	0.000197	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—RAF1—dilated cardiomyopathy	1.9e-05	0.000197	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.9e-05	0.000197	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.89e-05	0.000196	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	1.86e-05	0.000193	CbGpPWpGaD
Imatinib—CA9—Metabolism—GPX1—dilated cardiomyopathy	1.85e-05	0.000192	CbGpPWpGaD
Imatinib—CA1—Metabolism—AGT—dilated cardiomyopathy	1.84e-05	0.000191	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.83e-05	0.00019	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.83e-05	0.00019	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.81e-05	0.000187	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.81e-05	0.000187	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—RAF1—dilated cardiomyopathy	1.8e-05	0.000187	CbGpPWpGaD
Imatinib—CA9—Metabolism—CD36—dilated cardiomyopathy	1.8e-05	0.000187	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—RAF1—dilated cardiomyopathy	1.79e-05	0.000186	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.78e-05	0.000184	CbGpPWpGaD
Imatinib—KIT—Immune System—CD36—dilated cardiomyopathy	1.77e-05	0.000184	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ITGB1—dilated cardiomyopathy	1.77e-05	0.000184	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.77e-05	0.000183	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—RAF1—dilated cardiomyopathy	1.76e-05	0.000182	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.75e-05	0.000182	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	1.75e-05	0.000181	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	1.74e-05	0.00018	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.73e-05	0.000179	CbGpPWpGaD
Imatinib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	1.73e-05	0.000179	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	1.72e-05	0.000178	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.72e-05	0.000178	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.68e-05	0.000174	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD36—dilated cardiomyopathy	1.68e-05	0.000174	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	1.68e-05	0.000174	CbGpPWpGaD
Imatinib—KIT—Immune System—RAC1—dilated cardiomyopathy	1.67e-05	0.000173	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.65e-05	0.000171	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	1.64e-05	0.00017	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.63e-05	0.000169	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.63e-05	0.000169	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.63e-05	0.000169	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.63e-05	0.000169	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—RAF1—dilated cardiomyopathy	1.62e-05	0.000168	CbGpPWpGaD
Imatinib—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	1.62e-05	0.000168	CbGpPWpGaD
Imatinib—CA9—Metabolism—AGT—dilated cardiomyopathy	1.62e-05	0.000168	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—RAC1—dilated cardiomyopathy	1.58e-05	0.000164	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	1.58e-05	0.000164	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	1.57e-05	0.000162	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.56e-05	0.000162	CbGpPWpGaD
Imatinib—KIT—Disease—RAC1—dilated cardiomyopathy	1.54e-05	0.00016	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.51e-05	0.000157	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD36—dilated cardiomyopathy	1.51e-05	0.000157	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	1.48e-05	0.000154	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.48e-05	0.000153	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD36—dilated cardiomyopathy	1.48e-05	0.000153	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.47e-05	0.000153	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.47e-05	0.000152	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.47e-05	0.000152	CbGpPWpGaD
Imatinib—PDGFRA—Disease—RAC1—dilated cardiomyopathy	1.46e-05	0.000152	CbGpPWpGaD
Imatinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	1.45e-05	0.00015	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—RAC1—dilated cardiomyopathy	1.43e-05	0.000148	CbGpPWpGaD
Imatinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	1.42e-05	0.000148	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AGT—dilated cardiomyopathy	1.41e-05	0.000146	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.39e-05	0.000144	CbGpPWpGaD
Imatinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	1.39e-05	0.000144	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.39e-05	0.000144	CbGpPWpGaD
Imatinib—ALB—Hemostasis—CD36—dilated cardiomyopathy	1.38e-05	0.000144	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	1.35e-05	0.00014	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.32e-05	0.000137	CbGpPWpGaD
Imatinib—PDGFRB—Disease—RAC1—dilated cardiomyopathy	1.32e-05	0.000136	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.31e-05	0.000135	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.31e-05	0.000135	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—EGFR—dilated cardiomyopathy	1.31e-05	0.000135	CbGpPWpGaD
Imatinib—ALB—Hemostasis—RAC1—dilated cardiomyopathy	1.3e-05	0.000135	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	1.3e-05	0.000135	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.29e-05	0.000134	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.27e-05	0.000131	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.26e-05	0.000131	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.25e-05	0.00013	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.25e-05	0.00013	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.25e-05	0.00013	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—EGFR—dilated cardiomyopathy	1.24e-05	0.000128	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	1.23e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.21e-05	0.000126	CbGpPWpGaD
Imatinib—LCK—Immune System—CD36—dilated cardiomyopathy	1.21e-05	0.000126	CbGpPWpGaD
Imatinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.21e-05	0.000126	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.2e-05	0.000125	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.2e-05	0.000124	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.19e-05	0.000123	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.19e-05	0.000123	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.18e-05	0.000122	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	1.17e-05	0.000121	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.16e-05	0.00012	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.15e-05	0.000119	CbGpPWpGaD
Imatinib—LCK—Immune System—RAC1—dilated cardiomyopathy	1.14e-05	0.000119	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.14e-05	0.000118	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.13e-05	0.000117	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.13e-05	0.000117	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.13e-05	0.000117	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.12e-05	0.000116	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—dilated cardiomyopathy	1.11e-05	0.000115	CbGpPWpGaD
Imatinib—KIT—Immune System—RAF1—dilated cardiomyopathy	1.11e-05	0.000115	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	1.09e-05	0.000112	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RAC1—dilated cardiomyopathy	1.08e-05	0.000112	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.08e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.07e-05	0.000111	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.06e-05	0.00011	CbGpPWpGaD
Imatinib—LCK—Disease—RAC1—dilated cardiomyopathy	1.06e-05	0.00011	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—RAF1—dilated cardiomyopathy	1.05e-05	0.000109	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGT—dilated cardiomyopathy	1.03e-05	0.000107	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.03e-05	0.000107	CbGpPWpGaD
Imatinib—KIT—Disease—RAF1—dilated cardiomyopathy	1.02e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RAC1—dilated cardiomyopathy	1.02e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.02e-05	0.000106	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.02e-05	0.000106	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	1e-05	0.000104	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	9.79e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGT—dilated cardiomyopathy	9.78e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRA—Disease—RAF1—dilated cardiomyopathy	9.69e-06	0.0001	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.53e-06	9.88e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—RAF1—dilated cardiomyopathy	9.46e-06	9.8e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	9.34e-06	9.68e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.29e-06	9.63e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	9.26e-06	9.6e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GPX1—dilated cardiomyopathy	9.25e-06	9.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RAC1—dilated cardiomyopathy	9.22e-06	9.56e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	9.22e-06	9.55e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	9.1e-06	9.43e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.05e-06	9.38e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	9.02e-06	9.35e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CD36—dilated cardiomyopathy	9e-06	9.33e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	8.98e-06	9.3e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	8.94e-06	9.26e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.82e-06	9.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGT—dilated cardiomyopathy	8.81e-06	9.13e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CD36—dilated cardiomyopathy	8.74e-06	9.06e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—RAF1—dilated cardiomyopathy	8.73e-06	9.05e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—RAF1—dilated cardiomyopathy	8.65e-06	8.97e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GPX1—dilated cardiomyopathy	8.62e-06	8.93e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	8.58e-06	8.89e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CD36—dilated cardiomyopathy	8.39e-06	8.7e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	8.19e-06	8.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.19e-06	8.49e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	8.12e-06	8.42e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AGT—dilated cardiomyopathy	8.11e-06	8.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	7.94e-06	8.23e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AGT—dilated cardiomyopathy	7.87e-06	8.16e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—dilated cardiomyopathy	7.61e-06	7.88e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—RAF1—dilated cardiomyopathy	7.59e-06	7.87e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AGT—dilated cardiomyopathy	7.56e-06	7.83e-05	CbGpPWpGaD
Imatinib—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.49e-06	7.76e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	7.4e-06	7.67e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—dilated cardiomyopathy	7.2e-06	7.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RAF1—dilated cardiomyopathy	7.17e-06	7.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	7.07e-06	7.33e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—dilated cardiomyopathy	7.02e-06	7.28e-05	CbGpPWpGaD
Imatinib—LCK—Disease—RAF1—dilated cardiomyopathy	7.01e-06	7.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RAF1—dilated cardiomyopathy	6.79e-06	7.03e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	6.71e-06	6.96e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	6.69e-06	6.94e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—dilated cardiomyopathy	6.65e-06	6.89e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.56e-06	6.8e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	6.52e-06	6.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—dilated cardiomyopathy	6.49e-06	6.72e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	6.32e-06	6.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RAF1—dilated cardiomyopathy	6.12e-06	6.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—dilated cardiomyopathy	5.99e-06	6.21e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	5.87e-06	6.08e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—dilated cardiomyopathy	5.77e-06	5.97e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CD36—dilated cardiomyopathy	5.61e-06	5.82e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—dilated cardiomyopathy	5.21e-06	5.39e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	5.18e-06	5.36e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGT—dilated cardiomyopathy	5.06e-06	5.24e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	5.05e-06	5.24e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	5.04e-06	5.22e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.92e-06	5.1e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—dilated cardiomyopathy	4.92e-06	5.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	4.91e-06	5.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—dilated cardiomyopathy	4.81e-06	4.98e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	4.76e-06	4.93e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.72e-06	4.89e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—dilated cardiomyopathy	4.65e-06	4.82e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	4.64e-06	4.8e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.6e-06	4.76e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	4.54e-06	4.7e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	4.43e-06	4.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—dilated cardiomyopathy	4.19e-06	4.35e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.17e-06	4.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.14e-06	4.29e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	4.03e-06	4.18e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.93e-06	4.07e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.54e-06	3.66e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	3.37e-06	3.49e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.11e-06	3.23e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.03e-06	3.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.73e-06	2.83e-05	CbGpPWpGaD
